EMENDO BIOTHERAPEUTICS
Emendo was set up to expand what is possible in genome editing. They believe that challenges can be overcome by fusing expertise in diverse disciplines, and by looking at the core questions with a new approach. Having studied at top academic institutions, including the Weizmann Institute, Emendoโs founders came together to pool their collective knowledge of protein engineering and DNA repair to achieve a shared goal: the creation of genetic medicines that deliver on the promise of gene editing... . By transforming the available tools, they are able to address those disorders and diseases that are currently considered to be untreatable. Working at the cutting edge of gene editing, the Emendo team combines knowledge, expertise and proven scientific methodologies, with creativity, ingenuity and daring to push the boundaries and achieve more.
EMENDO BIOTHERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2015-05-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.emendobio.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
61 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
DNX Biotherapeutics
DNX Biotherapeutics is a Biotechnology company.
Current Employees Featured
Founder
Investors List
AnGes
AnGes investment in Series B - Emendo Biotherapeutics
Takeda Ventures
Takeda Ventures investment in Series B - Emendo Biotherapeutics
Official Site Inspections
http://www.emendobio.com Semrush global rank: 5.54 M Semrush visits lastest month: 1.53 K
- Host name: 87.186.102.34.bc.googleusercontent.com
- IP address: 34.102.186.87
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Emendo Biotherapeutics"
EmendoBio, Inc. - Crunchbase Company Profile
When was the last funding round for EmendoBio, Inc.? EmendoBio, Inc. closed its last funding round on Dec 15, 2020 from a Corporate Round round. Who are EmendoBio, Inc. 's competitors? Alternatives and possible competitors to โฆSee details»
EmendoBio | Our Story - Emendo Biotherapeutics
The idea behind EmendoBio began when a group of passionate graduates from the Weizmann Institute gathered around a whiteboard and asked a critical question โ โHow do we make CRISPR better? As the answer unfolded, a โฆSee details»
EmendoBio | Our Story | Investors
EmendoBioโs CRISPR-based technology provides an end-to-end platform capable of moving novel gene editing treatments from the initial stage of target indication, through drug composition, and to commercialization with scale and โฆSee details»
Company: Emendo Biotherapeutics - CRISPR Medicine
Emendo Biotherapeutics is a next-generation gene-editing company focused on developing novel nucleases for its proprietary CRISPR systems. The nucleases are being developed for โฆSee details»
Anocca AB Licenses Gene Editing Technology from EmendoBio Inc.
Mar 14, 2024 New York, USA, & Södertälje, Sweden, 14th March 2024 โ Anocca AB (Anocca), a leading T cell receptor-engineered T cell (TCR-T) cellular therapeutics company, and โฆSee details»
EmendoBio, Inc. - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Dec 15, 2020: ... Series A - โฆSee details»
Japanโs AnGes Acquires EmendoBio, Eying High โฆ
Dec 17, 2020 A nGes, Inc. is a biopharmaceutical company headquartered in Japan that specializes in gene-based medicines. On December 15 th, it announced the acquisition of Emendo Biotherapeutics, a CRISPR gene โฆSee details»
EmendoBio Gene Editing Company Acquired by AnGes, Inc.
Dec 15, 2020 NEW YORK & TEL AVIV, Israel & OSAKA, Japan--(BUSINESS WIRE)-- EmendoBio Inc., a leader in next-generation novel nuclease discovery and gene editing โฆSee details»
AnGes acquires EmendoBio, Inc. - 2020-12-15 - Crunchbase
Dec 15, 2020 AnGes acquires EmendoBio, Inc. on 2020-12-15 for $250000000. Search Crunchbase. Start Free Trial . Chrome Extension. ... Acquired Organization: EmendoBio, Inc. โฆSee details»
License agreement with Anocca AB for EmendoBio's โฆ
Mar 26, 2024 EmendoBio is now part of the Japanese firm AnGes Inc. after its acquisition of EmendoBio for $250 million in cash in late 2020. Up to that point, EmendoBio had managed to raise $73 million, with a ...See details»
EmendoBio | Our Culture - Emendo Biotherapeutics
We are problem solvers, never accepting existing limitations, always continuing to push boundaries until the right solution is found. Now with many bold scientists and engineers, who โฆSee details»
EmendoBio Gene Editing Company Acquired by AnGes, Inc.
Dec 15, 2020 EmendoBio Inc., a leading next-generation CRISPR gene editing company, acquired by AnGes, Inc. for $250 million.See details»
EmendoBio - BIO International Convention | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... EmendoBio is a gene editing โฆSee details»
David Baram: Founder and CEO of EmendoBio - wyantsimboli.com
Dec 16, 2023 David Baram: Founder and CEO of EmendoBio Dec. 16, 2023 Season: 6 Duration: 35:41 Episode: 66 David Barmam, founder and CEO of Emendio Biotherapeutics, โฆSee details»
EmendoBio ว Our Services
EmendoBio is an expert in gene editing with vast experience in the discovery of novel nucleases, engineering them, and development of CRISPR based gene editing compositions. We offer โฆSee details»
Emendo Biotherapeutics and Seattle Childrenโs Research Institute ...
Dec 22, 2021 EmendoBio is a next generation CRISPR gene editing company leveraging dual proprietary technology platforms to enable high precision gene editing throughout the genome. โฆSee details»
Emendo Biotherapeutics to Present New Data at 63rd ASH Annual โฆ
Dec 8, 2021 About Emendo Biotherapeutics EmendoBio is a next generation CRISPR gene editing company leveraging dual proprietary technology platforms to enable high precision โฆSee details»
EmendoBio | Our Science - Emendo Biotherapeutics
As a result, EmendoBio is uniquely positioned to treat indications that are dominant, dominant negative, and compound heterozygous, covering the majority of genetic disorders that other โฆSee details»
EmendoBio | Our Approach - Emendo Biotherapeutics
At EmendoBio, we do not believe in a one solution fits all gene editing approach. We believe the pathway to curing diseases is a tailor-made custom solution per target. The foundation of our โฆSee details»